New News Release
2017 16:12 | Monday
LARGE DNA CARGO GENOME ENGINEERING PROJECT
Geneva Biotech and Sphere Fluidics launch R&D project to develop methods that enable large DNA cargo delivery and genome engineering in primary cells that have proven refractory to traditional transfection, electroporation, or transduction methods. LINK
2017 16:11 | Saturday
NEW SYNBAC DEVELOPMENT MILESTONE
Geneva Biotech and partners have recorded >70% increase in baculovirus DNA stability in scale up experiments to 100L using second generation SynBac genomes. DNA stability was found to strongly correlate (r = 0.91) with expression yield of multiple different test proteins.
2017 17:41 | Friday
COMPETENT CELL PARTNER IN NORTH AMERICA
Intact Genomics is a world leader of ultra-high competent cell production and BAC (bacterial artificial chromosome) library related technologies. Intact has partnered with Geneva Biotech to offer North American customers competent cells containing Geneva Biotech’s viral genomes. See their Geneva Biotech partnered products here INTACT GENOMICS
2017 16:10 | Saturday
MTORC1 STRUCTURE SOLVED USING MULTIBAC
Aylett et al. published in Science (DOI: 10.1126/science.aaa3870) the structure of key drug target mTORC1 using the MultiBac system, providing critical information on the function and intricate regulation of this important enzyme which is implicated in common human diseases including cancer and diabetes.
2016 07:32 | Thursday
MULTIBACTAG: UNLOCKING PROTEIN COMPLEX CHEMICAL SPACE
Genetic code expansion (GCE) is a powerful method to incorporate artificial amino acids into polypeptide chains to create synthetic proteins with novel functions, with many applications ranging from discovery science to molecular medicine.
Until recently, this method has been mostly confined to small individual proteins representing a limited repertoire of cellular activity. Biological function in humans, however, is typically catalyzed by large protein machines, often comprising ten or more individual protein subunits. An international team of scientists from University of Bristol, EMBL and the Karlsruhe Institute of Technology have now developed MultiBacTAG, a powerful system to enable genetic code expansion in complex multiprotein machines.
2016 11:14 | Wednesday
LAUNCH OF KINASE FACTORY™
Developed by the European Union ComplexINC R&D consortium, Kinase Factory™
is a baculovirus expression system where entire 5-8 protein chaperone machineries specific for protein kinase folding were integrated into synthetic baculovirus genomes to provide a unique platform for production of kinases that display poor folding or stability. The system is also ideal for boosting production yields of kinases for large scale expression, e.g. for target production for drug discovery.
2015 11:12 | Wednesday
LAUNCH OF HORMONE RECEPTOR FACTORY™
Developed by the European Union ComplexINC R&D consortium, Hormone Receptor Factory™
is a baculovirus expression system where entire 5-7 protein chaperone machineries specific for hormone folding were integrated into synthetic baculovirus genomes to provide a unique platform for production of hormone receptors that display poor folding or stability. The system is also ideal for boosting production yields of hormone receptors for large scale expression, e.g. for target production for drug discovery.
2015 11:11 | Monday
LAUNCH OF COMPLEXLINK™
Developed at the European Molecular Biology Laboratory (EMBL), ComplexLink™
is a system of polyprotein production combined with co-production of sequence-specific proteases that co-translationally cleave the polyprotein into functional monomeric subunits. The technology provides unique advantages over existing expression systems for production of multiprotein complexes where subunit stoichiometry is difficult to control. The technology was applied to produce recombinant influenza polymerase complex from a self-processing polyprotein, as recently published in Nature (2014, 516:361-366).
2014 12:55 | Monday
EMBL GRANTS GENEVA BIOTECH EXCLUSIVE LICENSE ON MINIMIZED SYNTHETIC VIRAL GENOMES
The European Molecular Biology Laboratory (EMBL), Europe's flagship laboratory for basic research in molecular biology, has granted Geneva Biotech an exclusive license for intellectual property covering minimal baculoviral genomes. These genomes were created using modern synthetic biology techniques, and will appear in future as products "SynBac".
2014 23:18 | Tuesday
COMPLEXLINK™ TECHNOLOGY CATALYZES INFLUENZA R&D
The influenza polymerase remained inaccessible for decades – the challenge to produce this highly complicated protein complex for detailed analysis, proved to be a seemingly insurmountable technical challenge. The break-through studies, lead by Stephen Cusack, renowned influenza expert and Head of the EMBL Grenoble Outstation, used Geneva Biotech's ComplexLinkTM technology to produce recombinant influenza polymerase complex from a self-processing polyprotein, as recently published in Nature (
2014 20:20 | Saturday
GENEVA BIOTECH USA
Geneva Biotech has launched a subsidiary in Indianapolis, Indiana to provide better services to our US-based clients.
2014 12:30 | Monday
MULTICOLI™ TECHNOLOGY KEY TO UNRAVELLING MOLECULAR BIOLOGY MYSTERY
Membrane proteins constitute a large and important fraction of the proteome, with 80% of the druggable targets in cells being membrane proteins. The holotranslocon, a large transmembrane multiprotein complex comprising seven subunits catalyzes the entry of proteins into cell membranes. EMBL and UK based scientists used the MultiColi™ expression system in the ComplexINC R&D consortium to engineer a tightly regulated multigene co-expression circuit which enabled the functional assembly of holotranslocon complex published in the early edition of the Proceedings of the National Academy USA.
2013 12:11 | Monday
COMPLEXINC LARGE SCALE EUROPEAN UNION COLLABORATIVE GRANT
Geneva Biotech joins the ComplexINC R&D consortium for development of cutting edge new protein expression technologies.
2013 12:13 | Friday
SYNSIGNAL LARGE SCALE EUROPEAN UNION R&D COLLABORATIVE GRANT
Geneva Biotech joins the SynSignal R&D consortium for development of the next generation of synthetic biology tools and technologies.
2013 11:43 | Sunday
LAUNCH OF VLP FACTORY™ EXPRESSION SYSTEM
VLP Factory™ constitutively secretes promiscuous virus matrix proteins, with built in functionality to allow you to introduce multiple additional expression cassettes for production of multiprotein VLPs.
2013 12:27 | Saturday
LAUNCH OF MULTIMAM STABLE™
Developed as a variant of our transient mammalian multiprotein expression system, MultiMam Stable™ allows for easy DNA recombination-based assembly of multiprotein expression cassettes, followed by chromosomal integration and copy number expansion.
2013 16:41 | Thursday
LAUNCH OF SWEETBAC™
Developed through a collaboration between the University of Vienna and the European Molecular Biology Laboratory (EMBL), SweetBac™ is the world’s first baculovirus that produces humanized glycosylation patterns on recombinantly expressed proteins. SweetBac™ provides unique advantages over existing baculovirus expression systems for i) production of targets for drug discovery and assay development ii) antibody development against membrane proteins like GPCRs and ion channels, and iii) manufacturing of biologics in insect cells with humanized glycosylation patterns.
2013 11:02 | Sunday
MULTIBAC™ USED TO PRODUCE ANOTHER MASSIVE PROTEIN COMPLEX
The Berger Laboratory from EMBL Grenoble have described in molecular detail the architecture of the central scaffold of TFIID: the human protein complex essential for transcription from DNA to mRNA. The study, published today in Nature, opens new perspectives in the study of transcription and of the structure and mechanism of other large multi-protein assemblies involved in gene regulation. MultiBac™ has now been used in more than a dozen Nature and Science publications in the last 3 years.
2012 11:02 | Monday
EMBL GRANTS EXCLUSIVE TECHNOLOGY LICENSE TO GENEVA BIOTECH
The European Molecular Biology Laboratory (EMBL), Europe's flagship laboratory for basic research in molecular biology, has granted Geneva Biotech an exclusive license for intellectual property covering a portfolio of protein expression technologies. The company has also concluded a research collaboration agreement with EMBL.